L01XY01 · Antineoplastic and immunomodulating agents
Vyxeos liposomal (previously Vyxeos)
Indications
Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Composition
- Active substance
- daunorubicin hydrochloride, cytarabine
- International name (INN)
- daunorubicin;cytarabine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vyxeos liposomal (previously Vyxeos)
- Active substance
- daunorubicin hydrochloride, cytarabine
- ATC code
- L01XY01
- Therapeutic area
- Leukemia, Myeloid, Acute